incb123667
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started May 5, 2025 (NCT06909162)
Timeline
Indications
Mechanism of action
- Cyclin-dependent kinase 2INHIBITOR
CDK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07214779 | Phase 3 | Dec 1, 2025 | ENGOT Foundation, GOG Foundation, Inc., Incyte |
| NCT07218744 | Phase 1 | Nov 13, 2025 | Incyte |
| NCT07023627 | Phase 2 | Nov 12, 2025 | ENGOT Foundation, GOG Foundation, Inc., Incyte |
| NCT06909162 | Phase 1 | May 5, 2025 | Incyte |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Incyte | For profit | 4 | 4 | 3 | 2025 |
| ENGOT Foundation | Academic/Hospital | 2 | 0 | 2 | 2025 |
| GOG Foundation, Inc. | Academic/Hospital | 2 | 0 | 2 | 2025 |
3 organizations
Page 1 / 1